KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The mechanisms of oncogenic KRAS (KRAS*) in immune checkpoint blockade (ICB) therapy resistance remain unclear.
• Understanding KRAS* roles is crucial for improving ICB efficacy, particularly in colorectal cancer (CRC).

Purpose of the Study:

• To elucidate the biological functions and mechanisms of KRAS* in ICB therapy resistance.
• To identify potential therapeutic targets and patient selection strategies for enhancing ICB effectiveness in CRC.

Main Methods:

• Investigated the regulatory relationship between KRAS*, IRF2, and CXCL3 expression.
• Assessed the role of the KRAS*-IRF2-CXCL3-CXCR2 axis in myeloid-derived suppressor cell (MDSC) migration.
• Evaluated therapeutic strategies including enforced IRF2 expression and CXCR2 inhibition in preclinical models.
• Correlated IRF2 expression with anti-PD-1 therapy responsiveness in CRC patients.

Main Results:

• KRAS* represses IRF2 expression, which in turn represses CXCL3.
• KRAS*-mediated IRF2 repression leads to increased CXCL3, promoting MDSC migration via CXCR2.
• Enforced IRF2 expression or CXCR2 inhibition overcomes anti-PD-1 resistance in KRAS*-expressing tumors.
• Higher IRF2 expression in CRC correlates with increased responsiveness to anti-PD-1 therapy.

Conclusions:

• The KRAS*-IRF2-CXCL3-CXCR2 axis is a key mechanism underlying ICB resistance in KRAS*-driven cancers.
• Targeting this axis offers a promising strategy for overcoming ICB resistance and improving treatment outcomes in CRC.
• IRF2 expression can serve as a predictive biomarker for patient selection in ICB therapy.